Imagine having a window into the invisible world of your brain, where you can see the flow of blood coursing through its intricate vessels in real-time. That’s exactly what transcranial Doppler (TCD) allows us to do! This non-invasive diagnostic technique uses sound waves to measure changes in cerebral blood velocity, providing valuable information for diagnosing and treating cerebrovascular diseases (CVDs). Think of TCD as a medical detective, uncovering clues about occlusive CVDs, assessing collateral circulation after an ischemic stroke, and even monitoring the effects of treatments like thrombolysis. It can also help detect cerebral vasospasm and microembolization signals following an aneurysmal subarachnoid hemorrhage. TCD goes beyond diagnosis and monitoring – it can predict short-term stroke risk and guide interventions like endovascular therapy in patients with anterior circulation occlusion. Besides being a powerful research tool, TCD is increasingly playing a role in patient management. Exciting new research applications for TCD are on the horizon, expanding our understanding of these complex diseases. If you’re curious to learn more, dive into the fascinating world of TCD and its impact on cerebrovascular disease research.
Transcranial Doppler (TCD) is a rapid and non-invasive diagnostic technique that can provide real-time measurements of the relative changes in cerebral blood velocity (CBV). Therefore, TCD is a useful tool in the diagnosis and treatment of clinical cerebrovascular diseases (CVDs). In this review, the basic principles of TCD and its application in CVD were outlined. Specifically, TCD could be applied to evaluate occlusive CVD, assess collateral circulation in patients with ischemic stroke, and monitor cerebral vascular occlusion before and after thrombolysis as well as cerebral vasospasm (VSP) and microembolization signals after aneurysmal subarachnoid hemorrhage (SAH). Moreover, TCD could predict short-term stroke and transient cerebral ischemia in patients with anterior circulation occlusion treated with endovascular therapy and in patients with anterior circulation vascular occlusion. Additionally, TCD not only could monitor blood velocity signals during carotid endarterectomy (CEA) or carotid artery stenting (CAS) but also allowed earlier intervention through early recognition of sickle cell disease (SCD). Presently, TCD is a useful prognostic tool to guide the treatment of CVD. On the one hand, TCD is more commonly applied in clinical research, and on the other hand, TCD has an increasing role in the management of patients. Collectively, we review the principles and clinical application of TCD and propose some new research applications for TCD.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.